AFLAC INC
AFLAbout the company
Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. It operates in two segments, Aflac Japan and Aflac U.S. The Aflac Japan segment offers cancer, medical, nursing care, whole life, and GIFT insurance products, as well as WAYS and child endowment, and Tsumitasu insurance products in Japan. Its Aflac U.S.
Investment snapshot
Positive
5
BUY / PASS
Neutral / negative
4 / 6
NEUTRAL / FAIL
Median fair value
$102.82
-9.5% vs price
Models with upside
2 / 15
Positive margin of safety
Strongest signal
8 of 10 pass — Lynch and Schloss object
Key risk
All 4 investors flag AFL's efficiency
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
| Metric | O'Shaughnessy Systematic Factor Composite | Lynch GARP | Buffett Quality Compounder | Pabrai Dhandho Framework | Akre Three-Legged Stool | Schloss Asset-Value Discipline | Neff Low-P/E Total Return | Sleep Scale Economies Shared | Templeton Global Bargain Hunter | Marks Risk-Aware Value | Munger Quality Focus | Ackman Activist Value | Dreman Contrarian Value | Piotroski F-Score | Graham Defensive Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | NEUTRAL | FAIL | PASS | FAIL | FAIL | NEUTRAL | FAIL | FAIL | NEUTRAL | FAIL | NEUTRAL | PASS | PASS | PASS | PASS |
| Score | |||||||||||||||
| Analysis | |||||||||||||||
| Intrinsic Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||||||
| Margin of Safety | N/A | -3638.5% | N/A | -146.2% | +54.9% | N/A | N/A | N/A | -1.3% | N/A | N/A | N/A | +6.2% | N/A | -21.7% |
| Data As Of | 10-K (2026-08-25) | 10-K (2026-08-25) | 10-K (2026-08-25) | 10-K (2026-08-25) | 10-K (2026-08-25) | 10-K (2026-08-24) | 10-K (2026-08-24) | 10-K (2026-08-23) | 10-K (2026-08-23) | 10-K (2026-08-23) | 10-K (2026-08-23) | 10-K (2026-08-23) | 10-K (2026-08-23) | 10-K (2026-08-23) | 10-K (2026-08-23) |
Where It Passes
- Debt & Leverage80% pass✓ 10✗ 2▾
8 of 10 pass — Lynch and Schloss object
Total Debt / Equity0.29✓Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredDebt/Equity & Interest CoverageD/E: 0.29, IC: 21.9x✓BuffettD/E < 0.5 AND Interest Coverage > 5xDebt Levels0.29✓AkreDebt/Equity < 0.3✓MungerDebt/Equity < 0.5Total Debt / Shareholders' Equity0.29x✓SchlossD/E < 1.00x✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓Dreman< 0.8Current Assets / Current Liabilities✗SchlossCurrent ratio >= 1.50x (app cutoff)Interest Coverage & Debt/EBITDAIC=21.9x, D/EBITDA=1.8x✓MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity0.29✓Ackman<= 1.0LT Debt / Total Assets Change0.00% -> 0.00%✓PiotroskiDecreased YoY
Where It Falls Short
- Efficiency0% pass✗ 5▾
All 4 investors flag AFL's efficiency
ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROIC✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)1/2 years above 12% (latest 11.9%)✗SleepROIC > 12% in a majority of yearsReturn on Invested Capital✗Munger> 15%Revenue / Total Assets Change YoY0.16x -> 0.15x✗PiotroskiImproved YoY - Valuation9% pass✓ 5✗ 19▾
10 of 11 flag AFL's valuation — Oshaughnessy, Lynch, Pabrai +7 more
Revenue / market capitalization+0.3012; #3164/5203 (top 60.8%)✗OshaughnessyTop 10% of eligible cross-sectionNet income / market capitalization+6.40%; #1216/6251 (top 19.5%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date+3.60%; #2653/6203 (top 42.8%)✗OshaughnessyTop 10% of eligible cross-sectionBasic earnings-growth PEG (dividends excluded)37.39✗Lynch< 1.0 (ideally < 0.5)P/E or FCF YieldP/E=16.7x✗PabraiP/E < 15 or FCF Yield > 10%Price / Book Value per Share2.00x✗SchlossP/B <= 0.80x (app cutoff)✗Templeton< 1.5x✗Dreman< 1.2xPrice / Tangible Book Value per Share2.02x✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change+17.3%✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Price / Diluted EPS16.7x✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E0.15✗Neff> 0.7 (Neff's published traditional edge)Price / EPS16.7x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)✗Dreman< 12xPrice vs. Trailing Low114% of trailing low ($99.36)✓Templeton<= 120% of trailing low (certified split-adjusted live window)P/B or P/E vs. Historical AverageP/E=16.7x, P/B=2.0x✓MarksP/E < 15 or P/B < 2.0Discount to Intrinsic Value6.2% (IV=$121.15 vs Price=$113.66)✗Marks>= 20% below intrinsic valueValuation ReasonablenessP/E=16.7x, OE Yield=6.2%✓MungerP/E < 25 or Owner Earnings Yield > 5%Price / FCF per Share✗Ackman<= 25Price / (CFO / Shares)23.1x✗Dreman< 8xPrice / 3-yr avg EPS14.1x✓Graham<= 15xPrice-to-Book Ratio2.0x✗Graham<= 1.5xP/E x P/B28.10✗Graham<= 22.5 - Cash Flow10% pass✓ 2✗ 10▾
9 of 10 flag AFL's cash flow — Oshaughnessy, Lynch, Buffett +6 more
(Operating cash flow - capex) / market capitalization✗OshaughnessyTop 10% of eligible cross-sectionFCF Positive and Growing✗LynchPositive and growingFree Cash Flow Proxy✗BuffettPositive and growingP/E or FCF YieldP/E=16.7x✗PabraiP/E < 15 or FCF Yield > 10%Operating Cash Flow - Capital Expenditures✗Neff> $0 (app proxy for a strong fundamental case)Positive Operating Cash Flow frequency25/25 years positive✓SleepPositive OCF in >= 70% of available yearsFCF Positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap✗Ackman>= 4%Price / FCF per Share✗Ackman<= 25Price / (CFO / Shares)23.1x✗Dreman< 8xOperating Cash Flow$2.6B✓PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=2.19%, ROA=3.13%✗PiotroskiCFO/Assets > ROA - Profitability14% pass✓ 10✗ 18▾
12 of 14 flag AFL's profitability — Oshaughnessy, Lynch, Buffett +9 more
Net income / market capitalization+6.40%; #1216/6251 (top 19.5%)✗OshaughnessyTop 10% of eligible cross-sectionBasic earnings-growth PEG (dividends excluded)37.39✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR0.4%✓Lynch15-30% (Fast Grower); > 0% to passROE12.4%✗Lynch> 15%Net Income Positive (10+ years)28/28 years positive✓BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)20.2%✓Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)21.7% (latest)✓BuffettStable or rising over 10 yearsFree Cash Flow Proxy✗BuffettPositive and growingEarnings Variance (10-yr CoV)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdMargin of SafetyP/E=16.7x, P/B=2.0x✗PabraiP/B < 1.5 or P/E < 15Return on Equity18.1% (3-yr avg)✗AkreROE > 20% (3-year avg)Positive Diluted-EPS Years10/10 years positive✓Schloss>= 70% positive over 5-10 observed years (app rule)3-5 Year Diluted EPS CAGR0.4% over 5 years✗Neff7%-20% annualizedRevenue growth vs. gross and operating margin trend✗SleepRevenue rising; gross margin flat or falling; operating margin holding5-Year EPS CAGR0.4% CAGR over 5 years✓Templeton> 0% (5-year EPS CAGR)Operating Margin Trend✗TempletonNon-negative operating-margin trend over 3 yearsDiscount to Intrinsic Value6.2% (IV=$121.15 vs Price=$113.66)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency28/28 years positive✓MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue✗Ackman>= 15%Net Income / Shareholders Equity12.4%✗Ackman>= 15%Pre-Tax Income / Revenue26.4%✓Dreman>= 8%Net Income / Shareholders' Equity12.4%✓Dreman> 12%Net Income / Total Assets3.13%✓PiotroskiROA > 0ROA Change YoY4.63% -> 3.13% (delta: -1.50%)✗PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=2.19%, ROA=3.13%✗PiotroskiCFO/Assets > ROAPositive EPS (10 years)18/28 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growth - Growth25% pass✓ 4✗ 8▾
6 of 8 flag AFL's growth — Lynch, Neff, Sleep +3 more
Basic earnings-growth PEG (dividends excluded)37.39✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR0.4%✓Lynch15-30% (Fast Grower); > 0% to pass3-5 Year Diluted EPS CAGR0.4% over 5 years✗Neff7%-20% annualizedRevenue growth vs. gross and operating margin trend✗SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR-5.0%✗SleepCAGR > 7%5-Year EPS CAGR0.4% CAGR over 5 years✓Templeton> 0% (5-year EPS CAGR)Positive Net Income Frequency28/28 years positive✓MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth-2.3%✗Ackman>= 5%Positive EPS Growth Frequency3/5 years with positive EPS growth✓AckmanPositive EPS growth in >= 3 of last 5 yearsEPS Growth Direction✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedEPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growth - Valuation models33% pass✓ 2✗ 4▾
Models split on AFL at $113.66 — fair values range $3.04–$251.88
Lynch fair value$3.04✗Lynch-3638.5% margin vs $113.66Pabrai fair value$46.16✗Pabrai-146.2% margin vs $113.66Akre fair value$251.88✓Akre+54.9% margin vs $113.66Templeton fair value$112.23✗Templeton-1.3% margin vs $113.66Dreman fair value$121.15✓Dreman+6.2% margin vs $113.66Graham fair value$93.40✗Graham-21.7% margin vs $113.66 - Verdicts45% pass✓ 5✗ 6▾
Split decision: 6 FAIL · 5 PASS · 4 NEUTRAL
Overall verdict•OshaughnessyNEUTRAL (Not ranked)✗LynchFAIL (2/6)✓BuffettPASS (4/7)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)•SchlossNEUTRAL (4/7)✗NeffFAIL (1/6)✗SleepFAIL (2/6)•TempletonNEUTRAL (5/8)✗MarksFAIL (3/5)•MungerNEUTRAL (3/4)✓AckmanPASS (4/9)✓DremanPASS (4/10)✓PiotroskiPASS (F-Score 4)✓GrahamPASS (3/7)
Business & financials
Company Profile
Financial Snapshot
Insurers file unclassified balance sheets with no inventory or current accounts, so those criteria are omitted rather than failed for missing data. Return-on-invested-capital tests are omitted too: float funds the balance sheet but never appears in invested capital, and the portfolio it is invested in would be subtracted as spare cash. Debt tests are kept — an insurer’s borrowings are real leverage on top of underwriting.
Shareholder Return
Fiscal 2025
Retired 5.7% of shares last year, 10.3% over two.
- Buybacks
- $3.5B
- Dividends
- $1.2B
What drove EPS
A buyback raises earnings per share without the company earning more. This splits each year's change into the two.
The two parts do not sum exactly to the total — the difference is the cross-term, plus preferred capital where the company has any. It is left visible rather than distributed into the other two.
Share count is the denominator the filer used for diluted EPS, recovered as net income ÷ EPS — not the balance-sheet count, which is a point-in-time figure and would put the timing difference into this split. Years with a loss are omitted: a smaller share count makes a loss per share larger, so the decomposition inverts.
Company Financials
Annual data (10-K) · Last 5 years
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Market Cap | $57.0B | $57.5Best. | $46.5Best. | $42.1Best. | $37.2Best. |
| Revenue | $17.2B↓9% | $18.9B↑1% | $18.7B↓2% | $19.1B↓11% | $21.6B |
| Operating Income | -- | -- | -- | $4.2B↓16% | $4.9B |
| Net Income | $3.6B↓33% | $5.4B↑17% | $4.7B↑5% | $4.4B↑4% | $4.2B |
| EPS (Diluted) | $6.82↓29% | $9.63↑24% | $7.78↑18% | $6.59↑3% | $6.39 |
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | 21.7%↓5% | 22.9% |
| ROE | 12.4%↓41% | 20.9%↓2% | 21.2%↓3% | 21.9%↓12% | 24.8% |
| Total Debt | $8.4B↑12% | $7.5B↑2% | $7.4B↓1% | $7.4B↓6% | $8.0B |
| Shareholders' Equity | $29.5B↑13% | $26.1B↑19% | $22.0B↑9% | $20.1B↑18% | $17.0B |
| Current Ratio | — | — | — | — | — |
| Debt / Equity | 0.29↓1% | 0.29↓14% | 0.33↓9% | 0.37↓21% | 0.47 |
| Operating Cash Flow | $2.6B↓6% | $2.7B↓15% | $3.2B↓18% | $3.9B↓23% | $5.1B |
| Free Cash Flow | -- | -- | -- | -- | -- |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Insurance
AFL vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITEDHEALTH GROUP INCUNH | $336.5B | $374.94 | $447.6B | $12.1B | 12.0% | 0.78 | 4.2% | 0.79 | 3/7 | 4/7 | 0/6 | F-Score 6 | 3/10 |
| PROGRESSIVE CORP/OH/PGR | $122.2B | $210.52 | $87.7B | $11.3B | 37.3% | 0.23 | — | — | 2/7 | 2/7 | 5/6 | F-Score 6 | 8/10 |
| CHINA LIFE INSURANCE CO LTDCILJF | $107.4B | $3.80 | — | — | — | — | — | — | 3/7 | 1/7 | 3/6 | F-Score 5 | 5/10 |
| MARSH & MCLENNAN COMPANIES, INC.MRSH | $81.3B | $170.42 | $27.0B | $4.2B | 27.2% | 1.28 | 23.1% | 1.10 | 3/7 | 3/7 | 3/6 | F-Score 6 | 5/10 |
| Aon plcAON | $58.5B | $275.90 | $17.2B | $3.7B | 39.5% | 1.63 | 25.3% | 1.11 | 2/7 | 4/7 | 3/6 | F-Score 6 | 3/10 |
| HUMANA INCHUM | $46.5B | $386.87 | $129.7B | $1.2B | 6.7% | 0.70 | 2.1% | 2.00 | 3/7 | 2/7 | 0/6 | F-Score 4 | 4/10 |
| SUN LIFE FINANCIAL INCSLF | $44.0B | $79.06 | $30.6B | $2.6B | 14.5% | 0.33 | — | — | 3/7 | 3/7 | 2/6 | F-Score 6 | 5/10 |
| HARTFORD INSURANCE GROUP, INC.HIG | $34.8B | $125.85 | $28.4B | $3.8B | 20.2% | 0.23 | — | — | 4/7 | 3/7 | 4/6 | F-Score 7 | 8/10 |